Opna Bio
Opna Bio is a clinical-stage biopharmaceutical company focused on oncology, developing novel small-molecule and targeted-degrader therapeutics against key regulators of cancer, including the Hallmarks of Cancer. Its pipeline features OPN-6602 (an EP300/CBP inhibitor in Phase 1 for multiple myeloma, granted FDA Fast Track designation), zavabresib (OPN-2853, a BET inhibitor with Orphan Drug designation for myelofibrosis), multi-functional protein degraders, and additional programs targeting hematologic malignancies and solid tumors. The company operates from South San Francisco and San Diego, California, and Lausanne, Switzerland.
Opna Bio is profiled on the APIs.io network. Tagged areas include Company, Oncology, Biopharmaceutical, Pharmaceuticals, and Cancer.
Opna Bio’s developer surface includes engineering blog, support, and 16 more developer resources.
Kin Score
Terms of Service 1
What its API terms permit and prohibit, quoted from its own page.
Privacy & Data 1
Its role, the data it processes, retention and transfers, quoted from its own privacy page.
Eligibility 1
Who may sign up and where, quoted from its own terms.
AI Preferences 1
Its stance on AI training, inference and agents, quoted from its own pages.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Documentation 1
Reference material describing how the API behaves
Agent Surfaces 2
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 3
Pricing, plans, and the legal terms of use
Company 6
The organization behind the API
Other 4
Properties that don't map to a standard resource type
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.